WallStSmart

JBS N.V. (JBS)vsUSANA Health Sciences Inc (USNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JBS N.V. generates 8995% more annual revenue ($84.15B vs $925.26M). JBS leads profitability with a 2.5% profit margin vs 1.2%. JBS trades at a lower P/E of 13.8x. USNA earns a higher WallStSmart Score of 54/100 (C-).

JBS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 2.40

USNA

Buy

54

out of 100

Grade: C-

Growth: 3.3Profit: 5.0Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JBSSignificantly Overvalued (-132.0%)

Margin of Safety

-132.0%

Fair Value

$7.00

Current Price

$15.75

$8.75 premium

UndervaluedFair: $7.00Overvalued
USNASignificantly Overvalued (-432.0%)

Margin of Safety

-432.0%

Fair Value

$3.94

Current Price

$17.20

$13.26 premium

UndervaluedFair: $3.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JBS3 strengths · Avg: 8.3/10
Return on EquityProfitability
24.1%9/10

Every $100 of equity generates 24 in profit

P/E RatioValuation
13.8x8/10

Attractively priced relative to earnings

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

USNA2 strengths · Avg: 9.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

PEG RatioValuation
0.718/10

Growing faster than its price suggests

Areas to Watch

JBS3 concerns · Avg: 2.0/10
Profit MarginProfitability
2.5%3/10

2.5% margin — thin

EPS GrowthGrowth
-16.2%2/10

Earnings declined 16.2%

Debt/EquityHealth
2.561/10

Elevated debt levels

USNA4 concerns · Avg: 3.3/10
P/E RatioValuation
29.3x4/10

Moderate valuation

Market CapQuality
$313.95M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.0%3/10

ROE of 2.0% — below average capital efficiency

Profit MarginProfitability
1.2%3/10

1.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : JBS

The strongest argument for JBS centers on Return on Equity, P/E Ratio, Price/Book. Revenue growth of 13.4% demonstrates continued momentum.

Bull Case : USNA

The strongest argument for USNA centers on Price/Book, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.

Bear Case : JBS

The primary concerns for JBS are Profit Margin, EPS Growth, Debt/Equity. Debt-to-equity of 2.56 is elevated, increasing financial risk. Thin 2.5% margins leave little buffer for downturns.

Bear Case : USNA

The primary concerns for USNA are P/E Ratio, Market Cap, Return on Equity. Thin 1.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

JBS is growing revenue faster at 13.4% — sustainability is the question.

JBS generates stronger free cash flow (543M), providing more financial flexibility.

Monitor PACKAGED FOODS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

USNA scores higher overall (54/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

JBS N.V.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

JBS N.V., is a protein and food company globally. The company is headquartered in Amstelveen, Netherlands.

USANA Health Sciences Inc

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company is headquartered in Salt Lake City, Utah.

Want to dig deeper into these stocks?